Loading…
Tarsus Pharmaceuticals, Inc. is projected to rise to $71.06 by 2027, a +18% move from its current price of $60.06. TARS is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $58.62 | $60.07 | $61.55 | +0.01% |
| May 30 | $58.04 | $60.07 | $62.18 | +0.02% |
| May 31 | $57.59 | $60.08 | $62.66 | +0.03% |
| Jun 1 | $57.22 | $60.08 | $63.08 | +0.03% |
| Jun 2 | $56.90 | $60.09 | $63.45 | +0.04% |
| Jun 3 | $56.61 | $60.09 | $63.79 | +0.05% |
| Jun 4 | $56.34 | $60.10 | $64.10 | +0.06% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $56.34 | $60.10 | $64.10 | +0.06% |
| Week 2 | $54.89 | $60.13 | $65.87 | +0.12% |
| Week 3 | $53.81 | $60.17 | $67.27 | +0.18% |
| Week 4 | $52.92 | $60.20 | $68.49 | +0.24% |
| Week 5 | $52.15 | $60.24 | $69.58 | +0.30% |
| Week 6 | $51.47 | $60.28 | $70.59 | +0.36% |
| Week 7 | $50.86 | $60.31 | $71.53 | +0.42% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Tarsus Pharmaceuticals, Inc., ticker TARS, is a healthcare company focused on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospitals, pharmacies, and federal healthcare programs.
Tarsus Pharmaceuticals was incorporated in 2016 and is headquartered in Irvine, California. It is developing TP-04, a sterile aqueous gel formulation of lotilaner in Phase 2 trial for the treatment of ocular rosacea; and TP-05, an oral tablet formulation of lotilaner in Phase 2 trial for the prevention of Lyme disease, as well as in pre-clinical studies for community malaria reduction.
The company also exploits the lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention, and maintains development and licensing arrangements for regional expansion, such as China for TP-03 in Demodex blepharitis and meibomian gland disease.
Tarsus Pharmaceuticals, Inc. is currently priced at $62.26 per share with a market capitalization of $2.68B. It holds a rank position of 1814 in market size.
The price outlook, based on year-by-year projections through 2050, shows a path of growth with the 2026 average at $62.26 and the 2050 average at $465.10, accompanied by a potential upside of up to 647% in the far horizon. These figures point to a long-run bullish tilt despite a near-term neutral stance.
Overall, the forecast paints a durable upward trajectory over the multi-year horizon, with notable acceleration in the late 2020s and into the 2030s and beyond, contingent on market conditions and execution of development programs.
A major floor 13.9% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.7% away) — a key level to hold.
The nearest ceiling, 19.5% above — a clean break opens room to run.
A major ceiling 28.9% above — clearing it would confirm fresh momentum.
Key TARS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of TARS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $62.35 | Sell | $61.59 | Sell |
| MA 10 | $62.82 | Sell | $62.18 | Sell |
| MA 20 | $62.76 | Sell | $62.96 | Sell |
| MA 50 | $65.56 | Sell | $65.15 | Sell |
| MA 100 | $68.06 | Sell | $66.71 | Sell |
| MA 200 | $67.86 | Sell | $64.68 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 40.86 | Neutral |
| Stoch RSI (14) | 39.14 | Neutral |
| CCI (20) | -111.01 | Sell |
| Williams %R (14) | -92.59 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | -1.88 | Sell |
| Bollinger %B (20,2) | 0.13 | Neutral |
| Stochastic %K (14) | 7.41 | Buy |
| TRIX (15) | -0.26 | Sell |
| Awesome (5,34) | -2.14 | Sell |
| Ultimate (7,14,28) | 38.87 | Neutral |
| Momentum (10) | 0.23 | Buy |
| Aroon Osc (25) | 12.00 | Buy |
| Hull MA (9) | 61.27 | Sell |
| ADX (14) | 14.55 | Neutral |
| ATR (14) | 1.46 | Info |
The near-term technical picture is NEUTRAL, with RSI14 at 50.
Around-term momentum is guided by moving averages, with SMA50 at $65.87 and SMA200 at $67.73, placing the price in a zone around key averages.
Near-term support sits at $59.65 and resistance at $73.81, with a 30-day price range spanning from $52.70 to $73.55.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $59.65 | $60.06 | $76.37 | 0% | Neutral | |
| $56.95 | $71.06 | $93.58 | +18% | Neutral | |
| $69.95 | $89.40 | $121.60 | +49% | Bullish | |
| $74.48 | $97.11 | $135.51 | +62% | Bullish | |
| $79.00 | $104.83 | $149.51 | +75% | Bullish | |
| $83.25 | $112.27 | $163.20 | +87% | Bullish | |
| $86.01 | $117.75 | $174.15 | +96% | Bullish | |
| $88.95 | $123.49 | $185.51 | +106% | Bullish | |
| $94.81 | $133.39 | $203.30 | +122% | Bullish | |
| $114.28 | $162.86 | $251.55 | +171% | Bullish | |
| $141.12 | $213.03 | $348.17 | +255% | Bullish | |
| $270.70 | $450.73 | $800.40 | +650% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $59.65 | $60.06 | $70.27 | +0.00% |
| June 2026 | $50.52 | $59.20 | $70.90 | -1.44% |
| July 2026 | $51.28 | $60.53 | $73.38 | +2.25% |
| August 2026 | $51.55 | $61.21 | $74.89 | +1.12% |
| September 2026 | $49.84 | $59.47 | $73.32 | -2.84% |
| October 2026 | $49.17 | $58.92 | $73.14 | -0.92% |
| November 2026 | $50.32 | $60.54 | $75.60 | +2.74% |
| December 2026 | $50.36 | $60.81 | $76.37 | +0.46% |
Click any year to see its month-by-month TARS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect TARS to range from $59.65 to $76.37 through 2026. The $60.06 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The TARS price prediction for 2027 points to an average of $71.06 (low $56.95, high $93.58) — a potential gain of +18% on today's $60.06. Price action looks broadly range-bound.
In 2028, TARS is projected to trade between $69.95 and $121.60, averaging $89.40 — a potential gain of +49% from today's $60.06. That is up +26% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Tarsus Pharmaceuticals, Inc.'s 2029 outlook centres on $97.11, within a $74.48 to $135.51 range. That is up +9% on the projected 2028 average. That marks a +62% change versus current levels. Momentum favours further upside here.
By 2030, TARS could reach as high as $149.51, with a base case around $104.83 and support toward $79.00 — roughly +75% from $60.06. Buyers look set to stay in control over this stretch.
Expect TARS to range from $83.25 to $163.20 through 2031. The $112.27 average target implies a +87% move from current prices. That is up +7% on the projected 2030 average. Momentum favours further upside here.
The TARS price prediction for 2032 points to an average of $117.75 (low $86.01, high $174.15) — a potential gain of +96% on today's $60.06. Buyers look set to stay in control over this stretch.
In 2033, TARS is projected to trade between $88.95 and $185.51, averaging $123.49 — a potential gain of +106% from today's $60.06. That is up +5% on the projected 2032 average. Momentum favours further upside here.
Tarsus Pharmaceuticals, Inc.'s 2034 outlook centres on $133.39, within a $94.81 to $203.30 range. That is up +8% on the projected 2033 average. That marks a +122% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, TARS could reach as high as $251.55, with a base case around $162.86 and support toward $114.28 — roughly +171% from $60.06. Momentum favours further upside here.
Expect TARS to range from $141.12 to $348.17 through 2040. The $213.03 average target implies a +255% move from current prices. That is up +31% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The TARS price prediction for 2050 points to an average of $450.73 (low $270.70, high $800.40) — a potential gain of +650% on today's $60.06. Momentum favours further upside here.
Investing $1,000 in TARS today (≈ 16.650017 TARS) could be worth
$7,504.63
+$6,504.63 (+650%) by 2050 · US Dollar
Based on the average projected TARS price of $450.73 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in TARSwould be worth at today's price.
$1,000 invested in TARS on May 27, 2025 (≈ 23.877745 TARS) would be worth
$1,434.1
+$434.1 (+43.4%) today · 1.43× · US Dollar
Based on a TARS entry price of $41.88 vs. today's $60.06.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $64.79 | $926.99 | -7.3% |
| 1 month ago | $60.93 | $985.72 | -1.4% |
| 3 months ago | $75.87 | $791.62 | -20.8% |
| 6 months ago | $79.96 | $751.13 | -24.9% |
| 1 year ago | $41.88 | $1,434.1 | +43.4% |
| All time (5.0y) ago | $35.67 | $1,683.77 | +68.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our TARS forecast.
Our base-case forecast reaches $120.00 around 2033.
Implied market cap at $120.00: $5.16B
The multi-year forecast indicates a bullish trajectory through the 2030s and 2050, with steadily rising average prices and expanding ROIs.
By 2030, the average price is projected at $108.93 with an ROI of 75%.
By 2040, the average price rises to $220.25 with an ROI of 253.8%, and by 2050 the average price reaches $465.10 with an ROI of 647%.
These projections show strong upside potential across the later years, but they remain estimates and are not guaranteed; market dynamics, regulatory developments, and execution risks could alter outcomes.
Tap a question to reveal the answer.
2030 min $81.59, avg $108.93, max $156.50, ROI 75%, sentiment BULLISH.
Forecasts show a bullish trend from 2027 onward, with 2027 avg $73.84 and ROI 18.6%, rising to 2030 avg $108.93 (ROI 75%) and to 2050 avg $465.10 (ROI 647%); 2026 is neutral with avg $62.26 and ROI 0%.
Yes. 2029 avg $100.35 (max $140.97); 2030 avg $108.93 (max $156.50).
Current price $62.26; Market cap $2.68B.
30-day range low $52.70, high $73.55; support $59.65; resistance $73.81.
Tarsus Pharmaceuticals, Inc. Community Discussion
0Share your Tarsus Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.